Anderson Timothy
Directeur/Membre du Conseil chez Lycia Therapeutics, Inc.
Profil
Anderson Timothy is currently a Director at Cadent Therapeutics, Inc. He is also a Managing Director at Blue Owl Healthcare Opportunities Advisors LLC and a Partner at Cowen Investment Management LLC.
In addition, he serves as a board member at F2G Ltd., Anaveon AG, Autobahn Therapeutics, Inc., and Lycia Therapeutics, Inc. Previously, Mr. Timothy worked as a Director at Compass Therapeutics LLC and as an Independent Director at Cullinan Oncology LLC.
He also held positions as a Director at VectivBio Holding AG and VectivBio AG.
From 2019 to 2021, he served as a Director at Cullinan Oncology, Inc.Mr. Timothy completed his undergraduate degree at Bowdoin College in 2011.
Postes actifs de Anderson Timothy
| Sociétés | Poste | Début |
|---|---|---|
Cowen Investment Management LLC
 Cowen Investment Management LLC Investment ManagersFinance Cowen Investment Management LLC (Cowen Investment Management) is a venture capital subsidiary of Cowen, Inc. founded in 1997. The firm is headquartered in New York. | Private Equity Investor | 01/07/2014 |
Lycia Therapeutics, Inc.
 Lycia Therapeutics, Inc. BiotechnologyHealth Technology Lycia Therapeutics, Inc. is a biotechnology company, which engages in the developing technology that utilizes lysosome-targeting chimeras. It uses LYTACs platform to discover and provide therapeutics that degrade extracellular and membrane-bound proteins that drive a range of difficult-to treat diseases, including cancers and autoimmune conditions. The company was founded by Carolyn R. Bertozzi in 2019 and is headquartered in San Diego, CA. | Directeur/Membre du Conseil | - |
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Directeur/Membre du Conseil | - |
Anaveon AG
 Anaveon AG BiotechnologyHealth Technology Anaveon AG engages in the development of immune therapies against cancer. Its compounds promote effector T-cell functions to enhance a patient?s immune system to respond to tumors. The company was founded on December 11, 2017 by Onur Boyman and Andreas Katopodis and is headquartered in Bottmingen, Switzerland. | Directeur/Membre du Conseil | - |
Autobahn Therapeutics, Inc.
 Autobahn Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Autobahn Therapeutics, Inc. is a thyromimetics drug discovery company. It serves patients with neurodegenerative disorders. The company is headquartered in San Diego, CA. | Directeur/Membre du Conseil | - |
Cadent Therapeutics, Inc.
 Cadent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cadent Therapeutics, Inc. develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders. It focuses on modulating synaptic plasticity, the mechanism through which the brain builds and evolves the synaptic networks that carry out cognitive functions such as learning and memory. The company was founded by Kollol Pal, Frank S. Menniti, and Bertrand Leo Chenard in 2010 and is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | - |
Anciens postes connus de Anderson Timothy
| Sociétés | Poste | Fin |
|---|---|---|
| CULLINAN THERAPEUTICS, INC. | Directeur/Membre du Conseil | 07/01/2021 |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Directeur/Membre du Conseil | - |
Cullinan Oncology LLC
 Cullinan Oncology LLC Financial ConglomeratesFinance Cullinan Oncology LLC is a biopharmaceutical company, which engages in the development of a pipeline of targeted oncology and immuno-oncology therapies for cancer diseases. The company was founded by Patrick Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | - |
| ░░░░░░░░░ ░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
| ░░░░░░░ ░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Anderson Timothy
| Bowdoin College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CULLINAN THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 10 |
|---|---|
Compass Therapeutics LLC
 Compass Therapeutics LLC BiotechnologyHealth Technology Compass Therapeutics LLC operates as a healthcare industry focusing on biotechnology. It offers drug discovery, development, biologics, oncology and immuno-oncology. The company was founded by Errik B. Anderson and Thomas J. Schuetz in 2014 and is headquartered in Cambridge, MA. | Health Technology |
Cowen Investment Management LLC
Cowen Investment Management LLC Investment ManagersFinance Cowen Investment Management LLC (Cowen Investment Management) is a venture capital subsidiary of Cowen, Inc. founded in 1997. The firm is headquartered in New York. | Finance |
Lycia Therapeutics, Inc.
Lycia Therapeutics, Inc. BiotechnologyHealth Technology Lycia Therapeutics, Inc. is a biotechnology company, which engages in the developing technology that utilizes lysosome-targeting chimeras. It uses LYTACs platform to discover and provide therapeutics that degrade extracellular and membrane-bound proteins that drive a range of difficult-to treat diseases, including cancers and autoimmune conditions. The company was founded by Carolyn R. Bertozzi in 2019 and is headquartered in San Diego, CA. | Health Technology |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Health Technology |
Anaveon AG
Anaveon AG BiotechnologyHealth Technology Anaveon AG engages in the development of immune therapies against cancer. Its compounds promote effector T-cell functions to enhance a patient?s immune system to respond to tumors. The company was founded on December 11, 2017 by Onur Boyman and Andreas Katopodis and is headquartered in Bottmingen, Switzerland. | Health Technology |
Autobahn Therapeutics, Inc.
Autobahn Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Autobahn Therapeutics, Inc. is a thyromimetics drug discovery company. It serves patients with neurodegenerative disorders. The company is headquartered in San Diego, CA. | Commercial Services |
Cadent Therapeutics, Inc.
Cadent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cadent Therapeutics, Inc. develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders. It focuses on modulating synaptic plasticity, the mechanism through which the brain builds and evolves the synaptic networks that carry out cognitive functions such as learning and memory. The company was founded by Kollol Pal, Frank S. Menniti, and Bertrand Leo Chenard in 2010 and is headquartered in Cambridge, MA. | Health Technology |
Cullinan Oncology LLC
Cullinan Oncology LLC Financial ConglomeratesFinance Cullinan Oncology LLC is a biopharmaceutical company, which engages in the development of a pipeline of targeted oncology and immuno-oncology therapies for cancer diseases. The company was founded by Patrick Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA. | Finance |
VectivBio Holding AG
 VectivBio Holding AG Pharmaceuticals: MajorHealth Technology VectivBio Holding AG is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of treatments for severe rare conditions with significant unmet medical need. It operates through Switzerland, Canada, and the United States geographical segment. The company was founded by Luca Santarelli on May 22, 2019 and is headquartered in Basel, Switzerland. | Health Technology |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Health Technology |
